CA 19-9: Pancreatic Cancer Marker

The screening failure

CA 19-9's fatal flaw: it rises in benign conditions (pancreatitis, biliary obstruction, cholangitis, cirrhosis) and is NORMAL in ~10% of pancreatic cancers (Lewis-antigen negative individuals who cannot synthesize the marker). Combined, this renders it useless for population screening — CT/MRI own that role.

Where CA 19-9 helps

• Treatment-response monitoring: falling levels post-resection/chemotherapy track tumor burden
• Recurrence surveillance: rising levels precede radiographic recurrence by 2–6 months sometimes
• Prognostic stratification: markedly elevated pre-treatment levels associated with worse outcomes
• Symptomatic-mass triage: in jaundiced/pancreatitis patients with CT findings, adds correlative support

The biliary-obstruction confound

Jaundice itself elevates CA 19-9 dramatically — levels drop once bile flow restored. Always interpret CA 19-9 AFTER biliary stenting/drainage when possible, or account for obstruction in interpretation. Falsely reassuringly low levels during blockage mislead.

Thresholds and trends

Standard cutoff ~37 U/mL; levels >100–1000 strongly tumor-associated. Rising trends matter more than absolute values — post-resection nadir followed by consistent climb triggers imaging reassessment even before symptoms.